Key result
Catheter-directed thrombolysis was associated with reduced 30-day (3.1% vs 6.1%) and 1-year (8.2% vs 18.2%) mortality compared to standard medical therapy in patients with submassive pulmonary embolism.
Why the study?
Although catheter-directed thrombolysis reduces right ventricle strain in submassive pulmonary embolism, its impact on clinical outcomes remains unclear.
Does catheter-directed thrombolysis reduce mortality compared to standard anticoagulation in patients with acute submassive pulmonary embolism?
Population
Consecutive patients admitted to an ICU with acute submassive pulmonary embolism
Comparison
Catheter-directed thrombolysis vs systemic anticoagulation
Design
Retrospective propensity-score matched observational study
Follow-up
1 year
Authors
Loading...
May support consideration in submassive PE; leaves open need for randomized confirmation before practice change.
Observational
Does catheter-directed thrombolysis reduce mortality compared to standard anticoagulation in patients with acute submassive pulmonary embolism?
Absolute Event Rate: 3.1% vs 6.1%
Catheter-directed thrombolysis may reduce 30-day and 1-year mortality compared to standard anticoagulation in ICU patients with acute submassive pulmonary embolism without increasing bleeding risk.
D’Auria et al. (2019) conducted an observational in Acute submassive pulmonary embolism. Catheter-directed thrombolysis (CDL) vs. Systemic anticoagulation (medical therapy) was evaluated on Mortality at 30 days (propensity-score matched). Catheter-directed thrombolysis was associated with reduced 30-day (3.1% vs 6.1%) and 1-year (8.2% vs 18.2%) mortality compared to standard medical therapy in patients with submassive pulmonary embolism.
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: